ValuEngine upgraded shares of Zoetis (NYSE:ZTS) from a hold rating to a buy rating in a research note issued to investors on Monday, April 2nd.
A number of other equities research analysts also recently commented on ZTS. Morgan Stanley downgraded Zoetis from an overweight rating to an equal weight rating and set a $70.00 target price on the stock. in a research report on Monday, March 19th. They noted that the move was a valuation call. Jefferies Group set a $97.00 target price on Zoetis and gave the company a buy rating in a research report on Monday, February 26th. Barclays set a $77.00 target price on Zoetis and gave the company a hold rating in a research report on Saturday, February 17th. Deutsche Bank lifted their price objective on Zoetis from $76.00 to $78.00 and gave the company a hold rating in a research note on Friday, February 16th. Finally, Piper Jaffray set a $88.00 price objective on Zoetis and gave the company a buy rating in a research note on Friday, February 16th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $80.89.
Shares of NYSE ZTS traded up $1.27 during midday trading on Monday, hitting $85.67. The stock had a trading volume of 1,895,925 shares, compared to its average volume of 2,761,742. The company has a market cap of $40,552.65, a PE ratio of 35.70, a price-to-earnings-growth ratio of 1.87 and a beta of 0.96. Zoetis has a 1 year low of $53.05 and a 1 year high of $85.94. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.85 and a quick ratio of 2.55.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.59%. Zoetis’s dividend payout ratio is currently 20.83%.
In other news, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Heidi C. Chen sold 7,383 shares of the business’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $84.71, for a total value of $625,413.93. Following the completion of the sale, the insider now directly owns 20,162 shares of the company’s stock, valued at $1,707,923.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 112,952 shares of company stock valued at $9,219,843. Insiders own 0.35% of the company’s stock.
Several institutional investors have recently bought and sold shares of ZTS. Nordea Investment Management AB raised its stake in Zoetis by 4.7% during the 3rd quarter. Nordea Investment Management AB now owns 26,013 shares of the company’s stock valued at $1,659,000 after acquiring an additional 1,159 shares during the last quarter. Schroder Investment Management Group raised its stake in Zoetis by 306.0% during the 3rd quarter. Schroder Investment Management Group now owns 145,754 shares of the company’s stock valued at $9,229,000 after acquiring an additional 109,854 shares during the last quarter. BB&T Securities LLC raised its stake in Zoetis by 2.8% during the 3rd quarter. BB&T Securities LLC now owns 36,339 shares of the company’s stock valued at $2,317,000 after acquiring an additional 986 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Zoetis by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,321,904 shares of the company’s stock valued at $84,281,000 after acquiring an additional 5,047 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI purchased a new stake in Zoetis during the 3rd quarter valued at approximately $260,000. 92.33% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Zoetis (NYSE:ZTS) Rating Increased to Buy at ValuEngine” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://stocknewstimes.com/2018/04/17/zoetis-zts-upgraded-to-buy-at-valuengine.html.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.